Plain-English translation of NCT06526117 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing , a medication, to see if it can prevent strokes in children ages 5–12 with sickle cell disease who live in Nigeria. Strokes are a serious complication of sickle cell disease, especially in young children in Africa. The study hopes to show that this medication can work as an affordable alternative to blood transfusions, which are hard to access safely in many parts of Nigeria.
In the United States, doctors prevent strokes in children with sickle cell disease using regular blood transfusions, but this option is not realistic in Nigeria due to lack of safe blood supply, high costs, and the risk of serious side effects. Earlier research showed this medication may prevent strokes effectively and affordably, so this trial will test whether it truly works for children in Nigeria.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth daily, starting at a lower dose. Doctors will monitor you with regular visits and blood tests to check how well the medication works and to watch for any side effects. If you experience severe pain episodes during the trial, your dose may be increased to a moderate level. The study takes place at multiple centers in Nigeria and aims to follow children over time to see if the medication prevents strokes.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Nigeria